Assessing and Treating Pediatric ADHD: A Case Study
This paper presents a clinical case study of an 8-year-old girl referred for evaluation of attention deficit hyperactivity disorder (ADHD) based on teacher observations and behavioral assessments. Using Conner's Teacher Rating Scale-Revised, the paper documents subjective and objective findings from the patient and her family, then walks through three sequential pharmacological treatment decisions — transitioning from Wellbutrin to Strattera, from Intuniv to Focalin XR, and from Ritalin to Adderall XR. Each decision is evaluated in terms of clinical rationale, expected outcomes, and ethical considerations including nonmaleficence, autonomy, beneficence, and justice. The paper also addresses culturally competent care and medication side-effect management in pediatric ADHD populations.
- Case Introduction and Patient Background: Patient presentation, teacher observations, and mental status exam
- Decision 1: Transitioning to Strattera: Rationale for switching from Wellbutrin to atomoxetine
- Decision 2: Transitioning to Focalin XR: Switching from Intuniv to methylphenidate for better outcomes
- Decision 3: Transitioning to Adderall XR: Replacing Ritalin with Adderall XR for sustained effect
- Conclusion and Ethical Considerations in Pediatric ADHD Care: Side-effect management and culturally competent ADHD treatment
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each treatment decision follows a consistent structure: rationale for selection, reasons for rejecting alternatives, expected outcomes, and ethical considerations — making the clinical reasoning easy to follow.
- The paper integrates peer-reviewed evidence (e.g., Clemow et al., 2017; Pitzianti et al., 2020) alongside patient and family perspectives, balancing scientific and humanistic aspects of care.
- Ethical principles (nonmaleficence, autonomy, beneficence, justice) are applied concretely to each decision rather than discussed in the abstract, demonstrating applied clinical ethics.
Key academic technique demonstrated
The paper demonstrates sequential clinical decision-making, a technique common in nursing and psychiatric case presentations. Each decision builds on the outcome of the previous one, mimicking a real-world treatment progression where providers adjust medications based on patient response, side effects, and family feedback. This structure makes it easy to evaluate both the clinical logic and the evidence base at each step.
Structure breakdown
The paper opens with a detailed case introduction covering subjective reports, parent observations, teacher notes, and a mental status examination. Three treatment decision sections follow in sequence, each covering rationale, rejected alternatives, hoped-for outcomes, and ethical considerations. A brief conclusion synthesizes the overarching goals of pharmacological management, including side-effect monitoring and culturally competent care.
Case Introduction and Patient Background
An 8-year-old Caucasian girl is believed to suffer from attention deficit hyperactivity disorder (ADHD). Her teacher generated this referral after observing symptoms in the classroom, including inattentiveness, easy distractibility, forgetfulness, rapid loss of focus, poor spelling and grammar, and difficulty with reading and mathematics. Moreover, the girl pays attention only to things she finds personally interesting.
The teacher also notes that when the girl begins a task, she is unable to finish it. She becomes distracted and cannot find the focus to complete her assignments. Schoolwork no longer engages her, and she does not follow instructions consistently.
All of the above details were documented in Conner's Teacher Rating Scale-Revised, which was forwarded to the PMHNP for further evaluation of the patient's condition. The symptoms must be carefully reviewed before a diagnosis is made and relevant treatment is suggested.
The patient's parents deny her condition entirely. Her father stated he has never witnessed any temper issues. Her mother offered a similar response, saying that the girl would have been observed running around the house wildly if she suffered from such a condition — behavior that has never been seen at home.
When asked directly, the patient's subjective responses included that school is "okay," that she likes art and recess most, that the remaining subjects are boring to her, and that she is "usually lost" in class. She is self-aware enough to recognize that she feels lost during lessons. The teacher must call her name to draw her back from her thoughts; when asked, she is entirely unaware of what is being discussed.
The mental status examination reveals that her psychological state is normal, alert, clear, and coherent. Her dress is appropriate for the weather, and she displays appropriate mannerisms with the physician. She shows no mood disturbances, and visual and auditory signs are within normal limits. She denies any suicidal ideation or history of hallucinations. During the clinical interview, her attention was fully intact, with intact insight, judgment, and the ability to count backward from 100.
Decision 1: Transitioning to Strattera
The first decision is to discontinue Wellbutrin and begin Strattera (atomoxetine) 10mg daily by oral intake. The rationale for selecting this option is that it may be difficult for the parents to accept that the patient's thoughts of hurting herself are merely a side effect of Wellbutrin. Since parents are primarily concerned with their child's safety, it would be difficult to persuade them to continue the medication (Abar et al., 2021). The parents appeared sufficiently alarmed to consider calling the police, as they were reluctant to wake the doctor during the night.
The other two options were not selected because continuing the existing medication would likely heighten parental concern. Opting to begin Adderall would carry side-effect profiles similar to those of Strattera, so selecting one over the other would not produce a meaningful clinical difference in this regard (Cleveland Clinic, 2021; Llamas, 2022).
The expected outcome was that the patient would become more focused and calm, free from thoughts of self-harm. Research has corroborated the effectiveness of atomoxetine, demonstrating positive results in improving ADHD symptoms (Clemow et al., 2017). However, to maximize benefit, it is important to confirm that the patient does not have a comorbid depressive disorder beforehand — which is not the case here. Atomoxetine is therefore expected to produce encouraging results for the patient's inattentive ADHD presentation.
Ethical considerations for this decision include nonmaleficence, autonomy, justice, and beneficence (Peters, 2014). The parents must be fully informed about the side effects and possible outcomes of changing the medication so that they can provide informed consent. The physician must also ensure that the family does not feel ethnically discriminated against in the context of altered prescriptions and must act consistently in the patient's best interest.
Conclusion and Ethical Considerations in Pediatric ADHD Care
The three decisions described above are based on the principle that the child should be protected from maximum adverse drug effects that might create cultural concerns during pharmacological treatment. The physician must be culturally competent in understanding parental fears, as treating a child increases the stakes for each recommended medical intervention.
At each decision point, the side effects of the selected medication must be weighed against those of the alternatives so that the least harm is predicted for the patient. The medication changes are intended to address not only the child's health, but also the concerns of those around her — including her parents and teacher — whose observations and responses directly inform clinical decisions.
Certain commonly reported side effects, such as loss of appetite and sleep disturbances, must be monitored in relation to medication use and adherence in pediatric populations. The speed of medication response — as illustrated by the comparison of Adderall and Ritalin — should be carefully analyzed before prescribing to children, since morning and afternoon effects can produce significant changes in both physical and psychological functioning. The CDC provides guidance on evidence-based ADHD treatment approaches that can support clinical decision-making in complex pediatric cases such as this one.
Abar, C. C., Combs, A., Miley, A., Ruffino, R., & Abar, B. (2021). Parenting, health, and use of medications among college youth: The PHARMACY survey study. Preventive Medicine Reports, 24. https://doi.org/10.1016/j.pmedr.2021.101623
Attitude Mag. (2022, March 31). The top ADHD medications for children — rated by readers.
Clemow, D. B., Bushe, C., Mancini, M., Ossipov, M. H., & Upadhyaya, H. (2017). A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatric Disease and Treatment, 13, 357–371. https://doi.org/10.2147/NDT.S115707
Cleveland Clinic. (2021, January 7). Attention deficit hyperactivity disorder (ADHD): Nonstimulant therapy (Strattera) and other ADHD drugs. https://my.clevelandclinic.org/health/drugs/12959-attention-deficit-hyperactivity-disorder-adhd-nonstimulant-therapy-strattera--other-adhd-drugs
Hechtman, L. (2005). Effects of treatment on the overall functioning of children with ADHD. The Canadian Child and Adolescent Psychiatry Review, 14(Supplement 1), 10–15.
Llamas, M. (2022, April 27). Adderall side effects. Drug Watch.
Morris, S. Y. (2019, January 28). Adderall vs. Ritalin: What's the difference? Healthline. https://www.healthline.com/health/adhd/adderall-vs-ritalin
Peters, B. (2014). Ethics commentary: Ethical considerations in sleep medicine. Psychiatry Online, 12(1), 64–67.
Pitzianti, M. B., Spiridigliozzi, S., Bartolucci, E., Esposito, S., & Pasini, A. (2020). New insights on the effects of methylphenidate in attention deficit hyperactivity disorder. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.531092
Always verify citation format against your institution’s current style guide requirements.